ResMed (RMD) stock
NYSE
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $33.8B
- As of Nov 13, 2026
- P/E
- 21.21x
- Trailing twelve months
- P/B
- 5.68x
- Latest reported equity
- P/S
- 5.89x
- Trailing twelve months
- ROE
- 26.8%
- Trailing twelve months
- Dividend yield
- 1.00%
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $33.8B
- As of Nov 13, 2026
- P/E
- 21.21x
- Trailing twelve months
- P/B
- 5.68x
- Latest reported equity
- P/S
- 5.89x
- Trailing twelve months
- ROE
- 26.8%
- Trailing twelve months
- Dividend yield
- 1.00%
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
21.21x
P/B
5.68x
P/S
5.89x
Earnings and dividend metrics▾
Earnings
EPS
$11.29
Earnings per share
BPS
$42.18
Book value per share
ROE
26.8%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $11.29 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $42.18 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 26.8%.
Dividends
Yield
1.00%
Dividend per share
$2.40
Payout ratio
22.0%
Consecutive years
14+ yrs
Yield uses fiscal 2026 dividends · Dividend per share and payout ratio are for fiscal 2026.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $240.00 before tax.
- Payout ratio — 22.0% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 14 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2027 Q1)
Revenue increased 5.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.34B+5.9%
$1.23B
Jul–Sep '24
$1.34B
Jul–Sep '25
$1.42B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 30, 2026.
- Earnings per share increased 23.2% from the same quarter a year earlier.
- Revenue increased 5.9% from the same quarter a year earlier.
- Operating income increased 1.3% from the same quarter a year earlier.
- Net income increased 19.8% from the same quarter a year earlier.
Filed Oct 30, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Farrell Michael J.Chairman and CEO · Nov 11, 2026Shares withheld for taxes8,111 shares · $1.9MAvg. price $234.11
Show 3 price lots
- 3,466 shares × $234.11$811K
- 2,436 shares × $234.11$570K
- 2,210 shares × $234.11$517K
- Bloomer AaronChief Financial Officer · Nov 11, 2026Shares withheld for taxes1,095 shares · $256KAvg. price $234.117,977 shares held after
- Rider Michael JGlobal General Counsel · Nov 11, 2026Shares withheld for taxes1,944 shares · $455KAvg. price $234.11
Show 4 price lots
- 724 shares × $234.11$170K
- 547 shares × $234.11$128K
- 499 shares × $234.11$117K
- 173 shares × $234.11$40K
- FARRELL PETER CDirector · Nov 11, 2026Shares withheld for taxes169 shares · $40KAvg. price $234.1151,634 shares held after
- De Witte JanDirector · Nov 11, 2026Shares withheld for taxes60 shares · $14KAvg. price $234.114,201 shares held after
- Gill HarjitDirector · Nov 11, 2026Shares withheld for taxes36 shares · $8KAvg. price $234.109910,904 shares held after
- Farrell Michael J.Chairman and CEO · Nov 9, 2026Open-market sale4,993 shares · $1.2MAvg. price $235.3473479,803 shares held after
- Farrell Michael J.Chairman and CEO · Nov 9, 2026Option exercise4,993 shares · $731KAvg. price $146.34
Show 2 price lots
- 4,310 shares × $146.34$631K
- 683 shares × $146.34$100K
- Rider Michael JGlobal General Counsel · Oct 23, 2026Open-market sale400 shares · $102KAvg. price $25512,318 shares held after
- Farrell Michael J.Chairman and CEO · Oct 7, 2026Open-market sale4,991 shares · $1.1MAvg. price $226.3349479,803 shares held after
- Farrell Michael J.Chairman and CEO · Oct 7, 2026Option exercise4,991 shares · $730KAvg. price $146.34484,794 shares held after
- Farrell Michael J.Chairman and CEO · Sep 8, 2026Open-market sale4,991 shares · $1.1MAvg. price $222.4385466,256 shares held after
- Farrell Michael J.Chairman and CEO · Sep 8, 2026Option exercise4,991 shares · $730KAvg. price $146.34471,247 shares held after
- FARRELL PETER CDirector · Sep 2, 2026Open-market sale970 shares · $228KAvg. price $234.7351,803 shares held after
- Farrell Michael J.Chairman and CEO · Aug 14, 2026Grant or award13,547 shares · $0Avg. price $0479,803 shares held after
- Rider Michael JGlobal General Counsel · Aug 14, 2026Grant or award3,230 shares · $0Avg. price $012,718 shares held after
- Leong JustinChief Product Officer · Aug 14, 2026Grant or award6,461 shares · $0Avg. price $035,489 shares held after
- Bloomer AaronChief Financial Officer · Aug 14, 2026Grant or award9,072 shares · $0Avg. price $09,072 shares held after
- Farrell Michael J.Chairman and CEO · Aug 7, 2026Open-market sale4,991 shares · $1.0MAvg. price $205.6895466,256 shares held after
- Farrell Michael J.Chairman and CEO · Aug 7, 2026Option exercise4,991 shares · $730KAvg. price $146.34471,247 shares held after
- FARRELL PETER CDirector · Aug 5, 2026Open-market sale8,000 shares · $1.8MAvg. price $22552,773 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said net revenue for the 3 months ended September 30, 2026 was $1,415 million, up 6% from $1,336 million a year earlier. Diluted earnings per share for the same period were $2.92, compared with $2.37 a year earlier.Published Oct 30, 2026 · Filed Oct 30, 2026Read the summary →
- AI summary10-QResMed said net revenue for the quarter ended September 30, 2025 was $1,335.6 million, an increase of 9% from $1,224.5 million in the prior-year quarter (8% on a constant currency basis). The company cited increased demand and unit sales as factors for the Sleep and Breathing Health segment increase.Published Oct 10, 2026 · Filed Oct 31, 2025Read the summary →
- AI summary8-KResMed said revenue for the 3 months ended September 30, 2025 was $1,335.6 million, up 9% from $1,224.5 million in the prior year period (8% on a constant currency basis), and gross margin was 61.5%.Published Oct 9, 2026 · Filed Oct 30, 2025Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
ResMed (RMD) stock information
NYSE
ResMed (RMD) is listed on NYSE. Its market capitalization is about $33.8B. On trailing-twelve-month earnings the P/E ratio is 21.21, and the P/B ratio is 5.68. Return on equity is 26.8%. These figures are computed in-house from official filings and are reference information only.
ResMed — frequently asked questions
- What is the P/E ratio of ResMed (RMD)?
- On a trailing-twelve-month basis, RMD trades at a P/E ratio of 21.21. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of ResMed?
- RMD has a market capitalization of about $33.8B. The figure moves with the share price and is refreshed each trading day.
- Does ResMed pay a dividend?
- RMD has a dividend yield of about 1%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.